Opioid Epidemic Update (November/December)

Date of Issue: 11/01/2021 | Volume: 9 | Number: 7&8

Issue Links:Learning Objectives | Editorial Information

Dr. Capurso reviews the ins and outs of buprenorphine prescribing and provides tips for home-based inductions. Dr. Sharfstein discusses the current state of opioid overdose mortality in the age of COVID-19. We go over an evidenced based approach to decreasing suicide risk in our patients with addiction, and review findings on the effects of naltrexone for alcohol use disorder and antipsychotics in methamphetamine induced psychosis.

In This Issue

Expert Q&A

Buprenorphine Treatment

Topics: Addiction Treatment | Buprenorphine | Buprenorphine Induction | Detoxification | Medication for Opioid Use Disorder (MOUD) | Opioid Use Disorder

Buprenorphine is a first line medication for the treatment of opioid use disorder yet remains vastly under-prescribed. Here, Dr. Capurso reviews the pharmacologic principles relevant to buprenorphine prescribing and lays out how to start patients on the medication both in the clinic and at home.

Read More
Expert Q&A

Drug Overdoses in the US: Trends and Prevention Strategies

Topics: fentanyl | Harm reduction | Naloxone | Opioid epidemic | Opioids

Increases in drug overdose mortality continues unabated around the country driven by widespread availability of illicit fentanyl and methamphetamines. Dr. Sharfstein provides context to these concerning trends and discusses prevention and harm reduction strategies clinicians can implement for their patients.

Read More
Clinical Update

Suicide Safety Planning for the Patient with Addiction

Topics: Addiction | Safety Planning | Suicide

Addiction is a major risk factor for suicide. Here, we provide a practical guide to Safety Planning, an evidenced based approach for reducing suicide risk that can be implemented in a variety of clinical settings.

Read More
Research Update

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

Topics: Buprenorphine | fentanyl | induction | medication of opioid use disorder (MOUD) | Opioid Use Disorder

Avoiding buprenorphine induced withdrawal during induction can be particularly tricky for those using fentanyl. Researchers describe a novel induction dosing strategy that mitigates this risk.

Read More
Research Update

Buprenorphine Induction Without Withdrawal

Topics: Buprenorphine | Buprenorphine Induction | medication of opioid use disorder (MOUD) | Opioid Use Disorder

Making the switch from full opioid agonist to buprenorphine usually involves a period of withdrawal prior to starting the medication. Here, researchers describe a method of switching from full to partial opioid agonist by using small “microdoses” in order to avoid withdrawal.

Read More
Research Update

Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

Topics: Addiction Treatment | Buprenorphine | Medication for Opioid Use Disorder | Naltrexone | Opioid Use Disorder

Buprenorphine and long acting injectable naltrexone are both effective for the treatment of opioid use disorder; however, until now, we had little data to predict which patients would do better on which medications. Here, researchers identify patient characteristics predictive of success on buprenorphine versus naltrexone.

Read More
CME Post-Test

CME Post-Test - Opioid Epidemic Update, CATR, November/December 2021

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits.

Read More